
WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, or a stereoisomer or tautomer thereof, wherein:

m is 1;

n is 1, 2, or 3;

R^1 is $NR^{10}R^{12}$, and at least one of R^{10} and R^{12} is -C(O)C_{6-10} aryl, -C(O)C_{6-10} cycloalkyl or -C(O)HET;

R^2 is selected from the group consisting of: hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, C_{6-10} aryl, HET and $-NR^{10}R^{12}$, wherein each C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, are optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo and hydroxy, and C_{6-10} aryl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of oxo, halo, hydroxy, C_{1-4} alkyl and C_{1-4} haloalkyl;

each R^3 and R^7 is independently selected from the group consisting of hydrogen, C_{1-4} alkyl and C_{1-4} haloalkyl;

X is CH_2;

each R^5, R^6, $R^{8'}$ and R^8 is independently selected from the group consisting of hydrogen, halo, COOH, hydroxy, OC_{1-4} alkyl, C_{1-4} alkyl and C_{1-4} haloalkyl;

R^9 is 1,2,4-triazolyl, 1,2,3-triazolyl, or tetrazolyl;

R^{10} is selected from the group consisting of hydrogen, C_{1-4} alkyl, -C(O)C_{6-10} aryl, -C(O)C_{6-10} cycloalkyl, -C(O)HET and -C(O)C_{1-4} alkyl; wherein the C_{1-4} alkyl is optionally substituted with 1, 2, or 3 halo groups; wherein the -C(O)C_{1-4} alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, oxo, $-N(R^{11})_2$, HET, –O-C_{1-4} alkyl and C_{6-10} aryl; wherein the –O-C_{1-4} alkyl is

optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, oxo, -$N(R^{11})_2$ and C_{6-10} aryl; wherein the C_{6-10} aryl is optionally substituted with 1, 2, or 3 halo groups and wherein the -$C(O)C_{6-10}$ aryl, and -$C(O)C_{6-10}$ cycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, –O-C_{1-4} alkyl, –O-C_{1-4} haloalkyl and halo groups;

each HET is independently a mono- or bicyclic 5-10-membered heteroaryl or a mono- or bicyclic 5-10 membered heterocycloalkyl group, wherein each HET comprises 1, 2, 3, or 4 heteroatoms selected from O, S and N and is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, –O-C_{1-4} alkyl, –O-C_{1-4} haloalkyl, halo, hydroxy and oxo groups;

R^{11} is selected from hydrogen, C_{1-4} alkyl and C_{1-4} haloalkyl; and

R^{12} is selected from the group consisting of C_{1-4} alkyl, -$C(O)C_{6-10}$ aryl, -$C(O)C_{6-10}$ cycloalkyl, -C(O)HET and -$C(O)C_{1-4}$ alkyl; wherein the C_{1-4} alkyl is substituted with 1, 2, or 3 halo groups; wherein the -$C(O)C_{1-4}$ alkyl is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo,–O-C_{1-4} alkyl and C_{6-10} aryl; wherein the –O-C_{1-4} alkyl is substituted with 1, 2, or 3 halo; wherein the C_{6-10} aryl is substituted with 1, 2, or 3 halo groups and wherein the -$C(O)C_{6-10}$ aryl, and -$C(O)C_{6-10}$ cycloalkyl is substituted with 1, 2, or 3 halo groups.

2. The compound of claim 1, wherein R^2 is C_{1-6} alkyl.





3. The compound of claim 1, wherein each of R^3, R^6, R^7, R^8, and $R^{8'}$ is H.

4. The compound of claim 1, wherein R^1 is -$NR^{10}R^{12}$, and at least one of R^{10} and R^{12} is -$C(O)C_{6-10}$ aryl, -$C(O)C_{6-10}$ cycloalkyl, or -C(O)HET; R^2 is C_{1-6} alkyl; each of R^3, R^6, R^7, R^8, and $R^{8'}$ is H; and R^9 is 1,2,4-triazolyl, 1,2,3-triazolyl, or tetrazolyl.


5. The compound of claim 4, wherein R^1 is -$NR^{10}R^{12}$, in which R^{10} is H and R^{12} is -$C(O)C_{6-10}$ aryl or -C(O)HET.

6. The compound of claim 4, wherein R^2 is butyl.

7. The compound of claim 4, wherein R^{10} is H and R^{12} is -C(O)C_{6-10} aryl, or -C(O)HET; R^2 is butyl; and R^9 is 1,2,4-triazolyl, 1,2,3-triazolyl, or tetrazolyl.

8. The compound of claim 7, wherein R^2 is  and R^9 is , , or .

9. The compound of claim 1, wherein the compound is:



.


10. The compound according to claim 1, wherein at least one of R^1, R^2, and R^5 comprises fluorine or an isotope thereof.

11. The compound according to claim 10, wherein at least one of R^1, R^2, and R^5 comprises ^{18}F.


12. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

13. A method for imaging Granzyme B in a subject in need thereof, wherein a compound according to claim 10 is to be administered to said subject in an amount effective for imaging Granzyme B in the subject.


14. A compound of or a pharmaceutically acceptable salt thereof, or a stereoisomer or tautomer thereof, wherein the compound is one of the following:



,



,



and .